Chart 5.
Methodological quality assessment (risk of bias) corresponding to the randomized clinical trials, according to the checklist for randomized controlled trials tool made available by the JBI.
Studies conducted with/in: | Identification | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | “Yes” Score | Methodological quality | Risk of bias |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients | Marik et al. (23) | ? | + | + | - | + | + | + | NA | + | + | ? | + | + | 75% | High | Low |
Healthcare professionals | Anderson et al. (34) | ? | ? | + | + | - | + | + | + | + | + | ? | + | + | 69,2% | Moderate | Moderate |
Everson et al. (36) | ? | ? | + | - | - | - | ? | + | + | + | ? | + | + | 46.2% | Low | High | |
Boutin et al. (37) | + | ? | + | + | - | - | ? | + | + | + | ? | ? | + | 53.8% | Moderate | Moderate | |
Burden et al. (38) | + | ? | ? | - | - | - | + | + | + | + | ? | + | + | 53.8% | Moderate | Moderate | |
Bearman et al. (39) | ? | ? | + | + | - | + | + | - | - | + | ? | + | + | 53.8% | Moderate | Moderate | |
Romanò et al. (40) | ? | ? | + | + | - | + | ? | + | + | + | ? | + | + | 61.5% | Moderate | Moderate | |
Inanimate environments of healthcare | Wilson et al. (43) | + | ? | ? | + | - | - | ? | - | + | + | ? | + | + | 46.2% | Low | High |
Q1: Was true randomization used for assignment of participants to treatment groups?; Q2: Was allocation to treatment groups concealed?; Q3: Were treatment groups similar at the baseline?; Q4: Were participants blind to treatment assignment?; Q5: Were those delivering treatment blind to treatment assignment?; Q6: Were outcomes assessors blind to treatment assignment?; Q7: Were treatment groups treated identically other than the intervention of interest?; Q8: Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?; Q9: Were participants analyzed in the groups to which they were randomized?; Q10: Were outcomes measured in the same way for treatment groups?; Q11: Were outcomes measured in a reliable way?; Q12: Was appropriate statistical analysis used?; Q13: Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?; (+): Yes; (−): No; (?): Unclear; (NA): Not Applicable.